Investigators conducted a meta-analysis of randomized controlled trials to assess the efficacy and safety of brolucizumab ...

In response to a report of foreign material found in a sealed vial, Alcon Laboratories has initiated a voluntary recall of ...

As 2024 comes to a close, we here at Ophthalmology Times and the greater Eye Care Network would like to thank you–the reader.

Deepinder Dhaliwal, MD, LAc, explores advancements in managing Fuchs endothelial corneal dystrophy, highlighting Descemet ...

Electrical stimulation therapy is being explored as a potential treatment to enhance neuroplasticity and improve visual ...

Alon Kahana, MD, PhD, discusses the role of interleukin-6 in thyroid eye disease and the potential of tourmaline Bio's IL-6 ...

Deepinder Dhaliwal, MD, LAc, discusses longterm outcomes of Descemet Stripping Only (DSO) for Fuchs dystrophy at NYU's ...

A Helsinki University Hospital study found diabetes, glycemic control, or insulin therapy did not significantly affect ...

The NYU Grossman School of Medicine launches a Journal Club series with Ophthalmology Times, featuring expert faculty ...

A panelist discusses novel treatments for retinal vascular diseases, including faricimab, aflibercept, and ranibizumab.

Glaukos submitted an NDA for Epioxa, a novel corneal cross-linking therapy for keratoconus, to the US FDA. Epioxa's Phase 3 ...

Investigators conducted a retrospective clinical audit to determine why patients do not adhere to the guidelines among about 9,000 patients in a practice.